二甲双胍及其他糖尿病药物使用与新发干性年龄相关性黄斑变性的关联:病例对照研究
这项病例对照研究纳入2008至2017年新诊断年龄相关性黄斑变性(AMD)病例194135例及匹配对照193990例,分析二甲双胍使用与干性AMD发病风险的关联。多因素条件logistic回归显示,任何二甲双胍使用与干性AMD发病风险降低相关(OR=0.97;95%CI 0.95-0.99),2年累积剂量1-270g和271-600g亦相关。在无糖尿病视网膜病变的糖尿病患者中该关联持续存在,作者认为二甲双胍可能是预防干性AMD的策略。
要点
- 任何二甲双胍使用与干性AMD发病风险降低相关(OR=0.97;95%CI 0.95-0.99)。
- 2年累积剂量1-270g(OR=0.93)和271-600g(OR=0.92)与干性AMD风险降低相关。
- 无糖尿病视网膜病变的糖尿病患者中,二甲双胍使用与干性AMD风险降低相关(OR=0.97)。
核心结论
- 二甲双胍使用与干性AMD发病风险降低相关。
- 保护效应见于2年累积剂量低于601g。
- 在糖尿病患者中该关联持续存在,特别是在无糖尿病视网膜病变者中。
- 因此,二甲双胍可能是预防干性AMD发展的策略。
研究设计与样本
- 病例对照研究,纳入2008至2017年新诊断AMD病例194135例和匹配对照193990例,数据来自Merative MarketScan研究数据库。
- 糖尿病亚组包括49988例病例和49460例对照。
- 采用多因素条件logistic回归分析暴露对干性AMD发病的风险,主要结局指标为二甲双胍使用发生干性AMD的比值比(OR)。
主要发现
- 多因素条件logistic回归中,任何二甲双胍使用与干性AMD发病风险降低相关(OR=0.97;95%CI 0.95-0.99)。
- 2年累积剂量1-270g的二甲双胍使用与干性AMD风险降低相关(OR=0.93;95%CI 0.90-0.97),271-600g亦相关(OR=0.92;95%CI 0.89-0.96)。
- 糖尿病亚组中,每2年二甲双胍剂量低于601g与干性AMD风险降低相关(1-270g:OR=0.95;95%CI 0.91-0.99;271-600g:OR=0.92;95%CI 0.89-0.96)。
- 在无糖尿病视网膜病变的糖尿病患者中,任何二甲双胍使用与干性AMD风险降低相关(OR=0.97;95%CI 0.94-0.998),2年累积剂量1-270g(OR=0.96;95%CI 0.91-0.998)和271-600g(OR=0.92;95%CI 0.88-0.96)亦相关。
临床怎么用
- 原文结论指出二甲双胍可能是预防干性AMD发展的策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate if metformin use is associated with decreased odds of developing new non-neovascular ("dry") age-related macular degeneration (AMD). METHODS: Case-control study examining 194,135 cases with diagnoses of new-onset AMD between 2008 and 2017 and 193,990 matched controls in the Merative MarketScan Research Databases. The diabetic subgroup included 49,988 cases and 49,460 controls. Multivariable conditional logistic regressions identified the risks of exposures on the development of dry AMD. Main outcome measures were odds ratios (ORs) of developing dry AMD with metformin use. RESULTS: In multivariable conditional logistic regression, any metformin use was associated with decreased odds of developing dry AMD (OR = 0.97; 95% confidence interval [CI], 0.95-0.99). This protective effect was noted for cumulative 2-year doses of metformin of 1 to 270 g (OR = 0.93; 95% CI, 0.90-0.97) and 271 to 600 g (OR = 0.92; 95% CI, 0.89-0.96). In a diabetic subgroup, metformin use below 601 g per 2 years decreased the odds of developing dry AMD (1-270 g: OR = 0.95; 95% CI, 0.91-0.99; 271-600 g: OR = 0.92; 95% CI, 0.89-0.96). Unlike in diabetic patients with diabetic retinopathy, diabetic patients without diabetic retinopathy had decreased odds of developing dry AMD with any metformin use (OR = 0.97; 95% CI, 0.94-0.998) and cumulative two-year doses of 1 to 270 g (OR 0.96; 95% CI, 0.91-0.998) and 271 to 600 g (OR = 0.92; 95% CI, 0.88-0.96). CONCLUSIONS: Metformin use was associated with decreased odds of developing dry AMD. The protective effect was observed for cumulative 2-year doses below 601 g. In diabetics, this association persisted, specifically in those without diabetic retinopathy. Therefore, metformin may be a strategy to prevent development of dry AMD.
引用
- Kaufmann GT, Hyman MJ, Gonnah R, et al. Association of Metformin and Other Diabetes Medication Use and the Development of New-Onset Dry Age-Related Macular Degeneration: A Case-Control Study. Invest Ophthalmol Vis Sci. 2023. PMID: 37589984. doi:10.1167/iovs.64.11.22
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。